Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.10.2012 | main topic | Ausgabe 19-20/2012

Wiener Medizinische Wochenschrift 19-20/2012

FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours

Wiener Medizinische Wochenschrift > Ausgabe 19-20/2012
MD Philipp Malle, MD Manfred Sorschag, Univ.-Doz. MD Hans-Jürgen Gallowitsch


Gastrointestinal stromal tumours (GISTs) are fairly rare neoplasms, constituting less than 3 % of all gastrointestinal malignancies. The integration of molecularly targeted treatment regimes (i.e., tyrosine kinase inhibitors) in clinical oncology has revolutionized the management of patients with irresectable GISTs or metastatic disease. Malignant GISTs usually display increased glucose metabolism and therefore 18F-fluorodeoxyglucose (FDG) uptake within the scope of positron emission tomography (PET) scans. Nowadays, dual-modality FDG PET/CT (computed tomography) imaging is of considerable value in diagnostic work-up of patients with GISTs acquiring functional and anatomic information simultaneously. The following article sheds light on the impact of FDG PET and combined FDG PET/CT imaging in initial disease evaluation, detection of tumour recurrence and the early assessment of treatment response to molecularly targeted agents such as imatinib mesylate or sunitinib maleate.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Über diesen Artikel

Weitere Artikel der Ausgabe 19-20/2012

Wiener Medizinische Wochenschrift 19-20/2012 Zur Ausgabe